Role of glutathione in immunity and inflammation in the lung by Ghezzi, Pietro
© 2011 Ghezzi, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of General Medicine 2011:4 105–113
International Journal of General Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
105
REVIEW
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJGM.S15618
Role of glutathione in immunity and inflammation 
in the lung
Pietro Ghezzi
Brighton and Sussex Medical School, 
Trafford Centre, Falmer, Brighton, UK
Correspondence: Pietro Ghezzi
Division of Clinical and Laboratory 
Investigation, Brighton and Sussex 
Medical School, Trafford Centre, 
Falmer, BN1 9RY, United Kingdom
Tel +44 (0) 1273 873112
Fax +44 (0) 1273 876721
Email p.ghezzi@bsms.ac.uk
Abstract: Reactive oxygen species and thiol antioxidants, including glutathione (GSH), 
regulate innate immunity at various levels. This review outlines the redox-sensitive steps of 
the cellular mechanisms implicated in inflammation and host defense against infection, and 
describes how GSH is not only important as an antioxidant but also as a signaling molecule. 
There is an extensive literature of the role of GSH in immunity. Most reviews are biased by 
an oversimplified picture where “bad” free radicals cause all sorts of diseases and “good” 
antioxidants protect from them and prevent oxidative stress. While this may be the case in 
certain fields (eg, toxicology), the role of thiols (the topic of this review) in immunity certainly 
requires wearing scientist’s goggles and being prepared to accept a more complex picture. 
This review aims at describing the role of GSH in the lung in the context of immunity and 
inflammation. The first part summarizes the history and basic concepts of this picture. The 
second part focuses on GSH metabolism/levels in pathology, the third on the role of GSH in 
innate immunity and inflammation, and the fourth gives 4 examples describing the importance 
of GSH in the response to infections.
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Reactive oxygen species and oxidative stress
While the oxidative deterioration of lipids has been known for a long time, it was only 
in the late 1960s that we became aware of the importance of these chemical processes 
in pathology and toxicology with the finding that lipid peroxidation or rancidification 
occurred also in biological systems.1,2 The expression “oxidative stress” appears in 
the scientific literature in the 1970s. It implies that in aerobic organisms not only 
can molecular oxygen (O2) be reduced to water in the biochemical process known as 
respiration, which requires 4 electrons, but O2 can also be reduced to other intermedi-
ate species, between O2 and water, resulting from 1-electron reductive steps (Figure 1). 
These intermediates are superoxide radical (O2
−), hydrogen peroxide (H2O2), and 
hydroxyl radical (OH); they are all referred to as reactive oxygen species (ROS) and 
are extremely reactive because they avidly tend to reach the fully reduced state (H2O). 
Reactivity, in biological systems, is almost inevitably associated with toxicity, and 
ROS can damage various biological molecules: lipids (causing lipid peroxidation and 
membrane damage), DNA (causing DNA breaks), and proteins (causing, for instance, 
oxidation of various amino acids and inactivation of essential enzymes).International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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It is now thought that oxidative stress is implicated in the 
pathogenesis of several diseases and conditions, from aging 
to inflammation and carcinogenesis, if not as a primary cause 
of disease at least as an aggravating mechanism.
Antioxidant defenses and glutathione
The reality of oxidative stress is demonstrated by the exis-
tence, in all aerobic organisms, of several antioxidant 
enzymes devoted to ROS detoxification, such as peroxidase, 
catalase, superoxide dismutase, and peroxiredoxins. A num-
ber of small molecules also act as ROS scavengers. Unlike 
antioxidant enzymes, which catalyze the transformation of 
ROS into less toxic molecules, the concept of scavenger is 
that it must be an easily oxidizable target for ROS, and it 
must be present at concentrations high enough that the prob-
ability that a ROS reacts with the scavenger is higher than 
that of reacting with another target. When dealing with lipid 
oxidation (such as in rancidification of butter), the most 
important scavenger is probably vitamin E. As proteins with 
a sulfydryl group are often target of oxidation (–SH groups 
can be easily oxidized), small-molecular-weight thiols are 
potent scavengers.
The small thiol present in highest concentration in the 
cytoplasm is glutathione (GSH), a tripeptide glycine-cysteine- 
glutamic acid (Figure 2): the –SH group of its cysteine is 
extremely sensitive to oxidation, mainly by peroxides. Its 
importance is supported by the existence of a molecular 
machinery that makes it particularly effective. In fact, a 
scavenger, including any thiol antioxidant such as the com-
mon laboratory reagent beta-mercaptoethanol, would nor-
mally act as a suicidal decoy, being oxidized and thus 
becoming useless. However, when GSH is oxidized, it forms 
GSH disulfide (GSSG), and this can be re-reduced by a 
specific enzyme, glutathione reductase. Not only can GSH 
be enzymatically regenerated from GSSG, but also the 
  reaction of GSH with the ROS (a peroxide), which already 
takes place with high reactivity, is catalyzed by GSH per-
oxidases that facilitate the inactivation of a wide range of 
peroxides (Figure 3).
The key role of GSH as an antioxidant is demonstrated 
by many studies showing that experimental depletion of 
GSH levels – which can be achieved with various chemicals 
the most used of which is buthionine sulfoximine (BSO) 
an inhibitor of GSH synthesis – has a worsening effect in 
Respiration (full reduction to H2O):
Reductive intermediates (reactive oxygen species)
Superoxide radical
Hydrogen peroxide
Hydroxyl radical
2 H2O
H2O
O2 +4 e−
O2
−• O2 +e −
H2O2 +e −
OH· ++ e−
Figure 1 Reactive oxygen intermediates in the reductive metabolism of oxygen.
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many disease models. Conversely, repleting GSH levels 
with   precursors of its synthesis such as N-acetyl-cysteine 
(NAC) or 2-  oxothiazolidine-4-carboxylic acid has protec-
tive effects. Cysteine precursors, rather than cysteine itself, 
are used because they are more cell-permeable, and can be 
given orally.
Innate immunity and inflammation,  
two faces of the same biological coin
The first line of immune defense against pathogens, before 
adaptive immunity (antibodies, T cell responses) develops, 
is called innate immunity. This is a complex set of responses 
triggered when specific cells (macrophages, phagocytes, 
dendritic cells) recognize even a yet unknown pathogen by 
some characteristics common to most pathogens (these 
“signatures” are called pathogen-associated molecular pat-
terns) through a family of pathogen recognition receptors. 
This activates a response that involves production of ROS, 
a major bactericidal mechanism, and of soluble mediators 
(cytokines) whose role is to amplify the host response by 
recruiting and activating other immune system cells.
This aspect of the innate immune response is also 
known, from a different perspective, as the inflammatory 
response. Basically, the very same mechanisms and media-
tors of host defense are implicated in the pathogenesis of 
(noninfectious) inflammatory diseases, and inhibition of these 
mechanisms is the key to the mechanism of action of anti- 
inflammatory drugs.
Many noninfectious diseases of the respiratory system, 
including asthma, chronic obstructive pulmonary disease 
(COPD), cystic fibrosis, idiopathic pulmonary fibrosis 
(IPF), and oxygen toxicity, have an inflammatory 
  component. Inflammation is also implicated in the lung 
toxicity of ozone, asbestos, silica, cigarette smoke, and 
particulate matter. An exaggerated inflammatory response 
is also involved in the pathogenesis or complications of 
pulmonary infections such as tuberculosis, severe acute 
respiratory syndrome, influenza, and acute respiratory 
distress syndrome (ARDS).
Glutathione metabolism in disease
GSH synthesis and its precursors
GSH is synthesized from its 3 amino acids with a biosynthetic 
pathway shown in Figure 4. A study in humans, using 
radioisotopes,3 has demonstrated that the availability of 
cysteine,and its precursor methionine, is the rate-limiting 
factor in GSH synthesis. In general, it is assumed that the 
two main limiting factors are the levels of cysteine and of 
the enzyme gamma-glutamyl-cysteine synthetase (also 
known as glutamate-cysteine ligase).4
Genetic GSH deficiency and immunity
Glutathione synthetase (GS) deficiency (oxoprolinuria) is a 
rare autosomal recessive disorder affecting about 70 patients 
in the world. Patients with severe GS deficiency show, among 
other conditions, an increased susceptibility to bacterial 
infections.5,6
One case report showed that neutrophils from a child 
with GS deficiency undergo oxidative damage upon phago-
cytosis, indicating that GSH is important in defending the 
neutrophils from the ROS they produce as part of their 
microbicidal armamentarium.7 Of note, neutrophils from 
GS-deficient patients, despite normal phagocytosis and 
increased release of hydrogen peroxide, are less efficient in 
killing bacteria, indicating a helper role for GSH in the 
bactericidal activity.8
Acquired GSH deficiency and immunity
Many pathological conditions are associated with decreased 
GSH levels (Table 1). This could be due to several reasons. 
For instance, oxidative stress could cause GSH loss though 
oxidation. Another important aspect is nutrition, as it was 
shown that, even when dietary protein intake is sufficient for 
maintaining nitrogen balance, it may not be sufficient for 
maintaining cellular GSH, particularly in conditions of oxida-
tive stress.9 GSH deficiency could also arise from metabolic 
problems. For instance, in AIDS patients, a decrease in 
gamma-cystathionase activity in the liver was reported.10 
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Figure  4  Glutathione  (GSH)  biosynthesis.  1)  gamma-glutamyl  cyclotransferase; 
2) 5-oxoprolinase; 3) gamma-glutamylcysteine synthetase; 4) Glutathione synthetase. 
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The use of stable radioisotopes allowed the character-
ization of cysteine metabolism and GSH synthesis in 
  septic patients. This study showed that sepsis decreases 
blood GSH synthesis by 60%.3 Of note, these patients had 
an intake of sulfur amino acids below that recommended by 
the World Health Organization.3 Studies in animal models 
have reported an increased requirement for cysteine in 
sepsis, probably due to an increased turnover of GSH, as 
GSH synthesis accounts for 40% of the increased cysteine 
utilization.11,12 These and other studies show that even when 
the dietary intake of cysteine is sufficient for protein syn-
thesis (nitrogen balance), it may not be sufficient to maintain 
adequate GSH levels.9 One should also bear in mind that 
infectious and   inflammatory conditions are associated with 
an increased production of acute-phase proteins by the liver, 
and it was estimated that they account significantly for the 
increased utilization of sulfur amino acids, thus competing 
with GSH.13,14
GSH as a regulator of innate 
immunity
Anti-inflammatory role of GSH  
in lung diseases
The idea that GSH may play an anti-inflammatory role 
became popular in the 1990s with a study by Schreck et al15 
showing that antioxidants inhibit, whereas ROS activate, the 
transcription factor NF-κB that commands the transcription 
of several inflammatory genes,16 a role that has been con-
firmed in the lung.17
In fact, a protective role of GSH against inflammatory 
pathologies of the lung has been demonstrated by the protec-
tive effect of different GSH-precursors in various animal 
models (Table 2).
Along the same line, depleting endogenous GSH with 
BSO had a worsening effect in some of the models above, 
including chemically induced pulmonary edema,21 cigarette 
smoke,31 carrageenan-induced pleurisy,32 and endotoxin-
induced pulmonary inflammation.33
Table 1 Lung diseases associated with glutathione deficiency
Acute lung injury/acute respiratory distress syndrome
Chronic bronchitis
Chronic obstructive pulmonary disease
Cystic fibrosis
Idiopathic pulmonary fibrosis
Various bacterial and viral infections (including AIDS)
Toxicity of various foreign compound (smoke, pollutants, drugs ...)
Table 2 Protective effect of glutathione repletion in lung diseases
Disease Species Compound 
administered
Effect Reference
Asthma mouse GSH-ethyl ester,  
OTC
Decreased allergen-induced 
airway hyperresponsiveness 
and inflammation
18,19
Carrageenan 
pleurisy
rat NAC Decreased inflammation and 
oxidative stress; restored 
mitochondrial respiration
20
Chemically 
induced edema
rat NAC, cysteine 
dimethyl ester 
Protection against lethal doses 
of perfluoroisobutene
21
Idiopathic 
pulmonary fibrosis
patients NAC Preservation of vital capacity 
and carbon monoxide diffusing 
capacity
22
Bleomycin lung 
damage
rat NAC Decreased inflammation and 
fibrosis (hydroxyproline 
content)
23
Asbestosis rat NAC Reduced chrysotile-induced 
oxidative stress
24
Particulate matter 
lung damage
rat NAC Reduced histological 
alterations and inflammation
25
Hyperoxia rat, guinea pig OTC, NAC Reduced lung injury, alveolar 
hemorrage, and edema
26–28
Cystic fibrosis patients NAC Reduced inflammation 29
Smoke-induced 
inflammation
rat OTC Restoration of macrophage 
phagocytic functions
30
Abbreviations: GSH, glutathione; NAC, N-acetylcysteine; OTC, oxothiazolidine-4-carboxylic acid.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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It can bee seen that there is an overlap between the list 
of pulmonary diseases associated with inflammation and 
those where GSH repletion is protective, indirectly support-
ing the hypothesis of an anti-inflammatory role of GSH.
An increased susceptibility to sepsis-induced ARDS 
and lethality34 was observed in mice lacking the transcrip-
tion factor Nrf2, which has among its target genes the GSH 
biosynthetic enzyme gamma-glutamylcysteine synthase.35 
IPF is an example of lung disease in which normalizing the 
GSH deficit has positive effects. Patients with IPF have a 
4-fold lower GSH concentration in the epithelial lining fluid 
of the normal lower respiratory tract;36 moreover, the 
administration of the GSH precursor NAC not only restores 
GSH levels37 but, in association with other drugs used for 
the treatment of IPF, it also improves end points such as 
vital capacity and single-breath carbon monoxide diffusing 
capacity.22
GSH is essential for innate  
and adaptive immune functions
The functions of GSH are not only inhibitory as described 
above for the inflammatory response. In fact, GSH is essen-
tial for some functions of the immune system, both innate 
and adaptive, including T-lymphocyte proliferation,38,39 
phagocytic activity of polymorphonuclear neutrophils 
(PMN),40 and dendritic cell functions,41 and is also important 
for the first step of adaptive immunity, consisting of the 
antigen presentation by antigen-presenting cells (APC). 
Indeed, cell-mediated immunity requires that protein 
  antigens be first degraded in the endocytic vesicles of 
APCs (eg, macrophages, dendritic cells), so that the smaller 
peptides can be presented on the cell surface by the major 
histocompatibility complex to activate proliferation of 
antigen-specific T cells. One of the first steps in antigen 
degradation and processing is the reduction of disulfide 
bonds,42 which requires GSH.43 It should also be noted that 
although GSH inhibits the production of most inflammatory 
cytokines, it is required to maintain an adequate interferon-
gamma (IFN-gamma) production by dendritic cells,44 which 
is essential for the host defense against intracellular patho-
gens such as mycobacteria.45
This essential role of GSH in immunity might explain 
why in many diseases, not only AIDS, decreased GSH levels 
are associated with an increased susceptibility to infection. 
These include COPD,46 cystic fibrosis,47,48 influenza 
infection,49 and alcoholism,50,51 as ethanol impairs Th1/Th2 
balance via GSH depletion52 (Table 3).
GSH and immune defense against 
infection: four examples
Example 1: viral infections – oxidative 
stress and the pathogenesis of influenza
The role of oxidative stress in the pulmonary damage by 
influenza virus is well characterized in the mouse model. 
Mice infected with influenza show pulmonary damage associ-
ated with a dramatic decrease in pulmonary GSH levels as 
well as an increase of oxidative stress markers such as 
  oxidized glutathione (GSSG) and lipid peroxides.53 In these 
mice, oxidative stress could be due to the induction of 
  xanthine oxidase,54 a well-known superoxide-generating 
enzyme.55 Furthermore, influenza infection is associated 
with an induction of inflammatory cytokines,56,57 which might 
represent a likely GSH-sensitive step in its pathogenesis. 
Among the antioxidants shown to be protective in animal 
models of influenza are the xanthine oxidase inhibitor 
allopurinol,54 quercetin,58 superoxide dismutase,59 thioredoxin,60 
NAC (alone61 or with ribavirin62 or oseltamavir63), and GSH 
itself.64 A study reported that influenza virus M2 protein 
augments ROS production in human airway cells in vitro, 
resulting in toxic effects that are prevented by the addition 
of GSH ester.65 Although these studies indicate a protective 
role of GSH at the level of the pathogenesis of pulmonary 
damage, there is a report that BSO increases viral replication,66 
implying a possible antiviral role of endogenous GSH. One 
clinical study has shown that NAC administration improves 
parameters of cell-mediated immunity in patients with 
influenza,66 suggesting a possible clinical relevance of these 
observations.
Example 2: AIDS – importance  
of GSH in immunity
Historically, the entire field of the role of GSH in immunity 
and its effect on NF-κB received the strongest boost by studies 
on AIDS, particularly by a study from the group of Wulf Droge 
who showed that AIDS patients have a low concentration 
Table 3 Glutathione (GSH) depletion is associated with increases 
susceptibility to infections
Condition GSH  Infections
Alcoholism  
Chronic obstructive pulmonary disease  
Cystic fibrosis  
Influenza  
AIDS  International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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of plasma cysteine.67 The reasons for this are not clear, but 
AIDS patients have a deficit in the enzyme gamma cysta-
thionase, which synthesizes cysteine from the methionine.10 
Later research showed that AIDS causes a decrease in intra-
cellular GSH in CD4 T cells, and that low GSH is associated 
with decreased survival.68
The lower GSH levels in AIDS patients could have 
  various consequences. GSH depletion, at least in vitro, aug-
ments HIV replication,69 while its precursor NAC blocks 
the stimulatory effect of tumor necrosis factor on HIV 
  replication.70 Furthermore, the neurotoxic effect of HIV 
proteins Tat and gp120 is associated with oxidative stress 
and antagonized by NAC.71,72
Example 3: bacterial infections – 
tuberculosis
Mycobacterium tuberculosis is an intracellular pathogen that 
grows in the phagosomes, where it is protected from immune 
system effectors such as antibodies and T lymphocytes. 
Although the literature showing that GSH levels are lower 
in patients with tuberculosis dates back to the 1950s, it was 
not until the research of Venketaraman and colleagues that 
the effect of GSH on M. tuberculosis infection was studied 
in depth. Using a mouse macrophage cell line, the authors 
show that IFN-gamma and endotoxin increase both nitric 
oxide (NO) production and bactericidal activity; the paral-
leled decrease in GSH suggests that GSH reacts with NO to 
form S-nitrosoglutathione (GSNO). Under these experimen-
tal conditions, GSH depletion with BSO inhibited the micro-
bicidal activity of macrophages while its precursor NAC 
increased intracellular killing of mycobacteria also from 
human macrophages, which are normally not very effective 
in killing mycobacteria.73,74 Other investigators have shown 
that the trans-sulfuration pathway, which converts methionine 
into cysteine and has a key role in maintaining cysteine, and 
hence GSH levels, is essential for mycobacterial killing.75 In 
that study, it was found that not only are trans-sulfuration 
pathway enzymes increased in human monocytes as a 
response to mycobacteria, but their inhibitor propargylgly-
cine lowered GSH levels and inhibited clearance of myco-
bacteria and phagolysosome fusion, while NAC increased 
them.75 Similar results were obtained in whole human blood 
cultures.76 In vitro, both GSH and GSNO have direct bacte-
ricidal activity against these pathogens.77
This complex picture has been nicely reviewed by Connell 
and Venkataraman78 and is summarized in Figure 5. Depletion 
of GSH (by BSO or diethylmaleate) also inhibits macrophage 
leishmanicidal activity, as well as NO production, while the 
GSH precursor GSH-ethyl ester restores them,79 suggesting 
that the requirement for the GSH/NO pathway might be a 
common feature of resistance to intracellular pathogens.
Example 4: sepsis and its complications – 
GSH as a regulatory molecule
ARDS is one of the most serious complications in critically 
ill septic patients. Many studies have pointed out a role for 
oxidative stress in ARDS and shown a protective effect of 
GSH precursors.80,81
Most of the studies of ARDS in animal models, including 
those cited above, are based on the administration of 
lipopolysaccharide (LPS), a bacterial endotoxin. In mice, 
administration of LPS induces an acute lung injury similar 
to clinical ARDS, with production of inflammatory cytok-
ines, leukocyte infiltration in the lung, and pulmonary edema. 
In this model, various thiol-based antioxidants are 
protective.80–82 However, LPS administration is in fact a model 
of endotoxic shock, involving no live bacteria, to induce a 
state similar to what was once called septic shock and is now 
defined as systemic inflammatory response syndrome.83–85
However, in septic patients, survival is affected by 2 
opposite contributions of innate immunity: innate immunity 
is detrimental as systemic inflammation, which results in 
ARDS and shock, but on the other hand it is an essential 
component of the immune defense against infection. It is 
difficult to foresee how GSH affects this balance.
One more realistic animal model is that induced by cecal 
ligation and puncture (CLP), where puncturing the cecum 
causes the release of fecal material in the peritoneum that 
results in a polymicrobial peritoneal sepsis. This model 
allows studying the relevance of both arms of innate 
  immunity, the detrimental and the protective one.
ROS
NO
GSNO
GSH
BSO
Cysteine
NAC
BCG
IFN-g
LPS
iNOS
Figure 5 Glutathione in the defense against mycobacterial infections.
Abbreviations: IFN-g, interferon-gamma; LPS, lipopolysaccharide; ROS, reactive 
oxygen species; iNOS, inducible nitric oxide synthase; GSNO, S-nitrosoglutathione; 
GSH,  glutathione;  BCG,  bacillus  Calmette-Guérin;  BSO,  buthionine  sulfoximine; 
NAC, N-acetyl-cysteine.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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We have used this model to study the role of endogenous 
GSH in sepsis.86 In this model, CLP induced PMN infiltration 
in the peritoneal cavity, the site of infection, as well as in the 
lung, ultimately resulting in lung injury and death, with a 
concomitant decrease in endogenous GSH.86 Lowering GSH 
further with BSO worsened the clinical settings. Not only 
did BSO increase PMN infiltrate in the lung, but it also 
diminished PMN infiltration in the site of infection, thus 
increasing bacterial growth. As a result we had more inflam-
mation and less immunity, and survival was dramatically 
decreased. Repleting GSH with NAC had the opposite effect 
of reducing PMN infiltration to the lung but increasing that 
to the site of infection, thus decreasing bacterial colonies.
The picture that emerges from these experiments is that 
endogenous GSH is not just an inhibitor of inflammation, 
but it is required to allow a proper response to infection, and 
“direct” the migration of inflammatory PMN away from the 
lung, where they cause ARDS, and towards the site of infec-
tion, where they kill bacteria (Figure 6).
The idea, therefore, is that GSH is not just an inhibitor 
of inflammation but also a regulator of innate immunity in a 
direction favorable to the host.
Conclusions: GSH from a simple 
free-radical scavenger  
to a regulatory molecule
In parallel to the studies of GSH in immunity, more complex 
molecular and biochemical studies have pointed out a 
  regulatory role of GSH. This was a result of an evolution 
from the concept of oxidative stress outlined above to that 
of redox regulation. The concept of redox regulation implies 
that some oxidative changes (such as changes in the redox 
state of protein cysteines) are not necessarily damaging but 
can have regulatory properties. While this idea shows a more 
complex picture from the popular one where free radicals 
and oxidants are bad and antioxidants are good, it implies 
that GSH is an essential molecule not only in acting as an 
antioxidant but also in the absence of oxidative stress, as an 
endogenous signaling molecule. The molecular mechanisms 
of GSH-mediated redox regulation are being actively inves-
tigated and have in part been identified.87–89
Although the present review focused on the immuno 
pathogenesis of pulmonary diseases, the key concepts out-
lined here may help in interpreting the role of redox in other 
pathological conditions.
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